Session Time: 1:15pm-2:45pm
Location: Agora 3 West, Level 3
Objective: To investigate the effects of subthalamic nucleus deep brain stimulation (STN-DBS) on constipation and olfaction in patients with Parkinson disease (PD).
Background: STN-DBS is an effective therapy for selective motor complications of PD. There is limited evidence, based on self-rated assessments, that DBS also improves non-motor symptoms, such as constipation and hyposmia in PD. Therefore, we used objective techniques to study the effects of DBS on constipation and olfaction in PD.
Method: In this prospective study, PD patients evaluated in the DBS Clinic at Mayo Clinic Rochester between 2015-2018 were screened for constipation. Assessments, before and 3 months after DBS, included: (i) Constipation – ROME III questionnaires and daily bowel diaries for 4 weeks, (ii) Olfaction – 40-item University of Pennsylvania Smell Identification Test (UPSIT), (iii) Anxiety and depression – Hospital Anxiety and Depression Scale (HADS). The levodopa equivalent daily dose (LEDD) was calculated for PD medications. Comparisons were performed with Chi-squared and paired t-tests.
Results: Of 15 recruited patients, 5 withdrew. Ten patients (8 male, mean age 67.4 years, mean PD duration 6.5 years, mean UPDRS part III score off-medication 33.7) had a mean follow-up of 3 months post-DBS. At baseline, 8 patients met ROME III criteria for constipation vs. 2 of these patients after DBS (X2=7.2, p=0.01). Amongst the 4 patients who completed bowel diaries, the mean increase in bowel movement frequency/week (5.4±1.9 vs. 6.3±1.7, p=0.18) and consistency (2.3±0.9 vs. 3.0±0.8, p=0.39) after DBS failed to reach significance. Laxative use did not change. Mean UPSIT scores (20.0±6.6 vs. 17.5±5.7, p=0.03) worsened from severe to total hyposmia. Anxiety scores (5.8±3.2 vs. 4.8±2.7, p=0.14) and depression scores (4.9±3.0 vs. 4.8±2.9, p=0.89) were unchanged. Mean baseline LEDD was 1702.5±726.8 vs. 1419±555.9 (p=0.15) post-DBS.
Conclusion: In this small, uncontrolled study, olfaction worsened and fewer patients met Rome III criteria for constipation at 3 months after STN-DBS. These findings were neither associated with changes in bowel habits recorded by diaries, nor laxative use, PD medications, or mood. This suggests that STN-DBS may directly affect constipation and olfaction. These preliminary findings should be confirmed by a larger study with longer follow-up.
References: 1. Volkmann J. Deep brain stimulation for the treatment of Parkinson’s disease. J Clin Neurophysiol. 2004 Jan-Feb;21(1):6-17. 2. Zibetti M, Torre E, Cinquepalmi A, Rosso M, Ducati A, et al. Motor and nonmotor symptom follow-up in Parkinson patients after deep brain stimulation of the subthalamic nucleus. Eur Neurol. 2007;58(4):218-23. 3. Hwynn N, Haq IU, Malaty IA, Resnick AS, Dai Y, et al. Effect of Deep Brain Stimulation on Parkinson’s Nonmotor Symptoms following Unilateral DBS: A Pilot Study. Parkinson Disease, 2011. Doi: 10.4061/2011/507416. 4. Chou KL, Taylor JL, Patil PG. The MDS-UPDRS tracks motor and non-motor improvement due to subthalamic nucleus deep brain stimulation in Parkinson disease. Park Related Disord 2013;19:966-969. 5. Klingelhoefer L, Samuel M, Chaudhari KR, Ashkan K. An Update on the Impact of Deep Brain Stimulation on Non Motor Symptoms in Parkinson’s Disease. J Parkin Disease 2014;4:289-300. 6. Halim A, Baumgartner L, Binder DK. Effect of deep brain stimulation on autonomic dysfunction in patients with Parkinson disease. J Clin Neuroscience 2011;18:804-806. 7. Nazzaro JM, Palwa R, Lyons KE. The impact of bilateral subthalamic stimulation on non-motor symptoms of Parkinson’s disease. Parkin Related Disord 2011;17:606-609. 8. Bharucha AE, Seide B, Zinsmeister AR, Melton IJ III. Insights into normal and disordered bowel habits from bowel diaries. Am J Gastroenterol 2008; 103(3):692-8. PMID: 18021288 9. Guo X, Gao G, Wang X, Li L, Li W, et al. Effects of Bilateral Deep Brain Stimulation of the Subthalamic Nucleus on Olfactory Function in Parkinson’s Disease Patients. Stereotactic and Functional Neurosurgery, 2008:86;237-244. 10. Fabbria M, Guedes LC, Goelho M, Simao D, Abreu D, et al. Subthalamic deep brain stimulation effects 11. Double KL, Rowe DB, Hayes M, Chan DK, Blackie J, et al. Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Arch Neurol 2003 Apr;60(4);545-9.
To cite this abstract in AMA style:S. Kola, A. Bharucha, D. Prichard, K. Feuerhak, A. Hassan. A Prospective Study of the Effects of Deep Brain Stimulation on Constipation and Olfaction in Parkinson Disease [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/a-prospective-study-of-the-effects-of-deep-brain-stimulation-on-constipation-and-olfaction-in-parkinson-disease/. Accessed December 2, 2023.
« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/a-prospective-study-of-the-effects-of-deep-brain-stimulation-on-constipation-and-olfaction-in-parkinson-disease/